



J. A. RAJANI & CO.
CHARTERED ACCOUNTANTS

PRITESH J. RAJANI
B. COM., F.C.A., D.I.S.A.

1/8, Ground Floor, Bhagwan Raja Nagar,
Patel Estate Rd, Jogeshwari (W), Mumbai - 102.
Tel.: 2679 6678 / 2678 2680
Email: jarajanica@rediffmail.com

Independent Auditor's Report

To the Members of Avery Pharmaceuticals Private Limited

Report on the Financial Statements

We have audited the accompanying financial statements of Avery Pharmaceuticals Private Limited ("the Company"), which comprise the Balance Sheet as at 31st March, 2018 and Statement of Profit and Loss (including Other Comprehensive Income) and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Ind AS financial statements that give a true and fair view of the financial position, financial performance (including Other Comprehensive Income) and changes in Equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified in Companies (Indian Accounting Standards) Rules, 2015 (as amended) under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these Ind AS financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit of the Ind AS financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Those Standards and pronouncements require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Ind AS financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.



Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2018, its profits including other comprehensive income and changes in equity for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in Para 3 and 4 of the Order.

2. As required by Section 143 (3) of the Act, we report that:

(a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

(b) in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;

(c) the balance sheet and statement of profit and Loss (including other Comprehensive Income) and the Statement of Changes in Equity dealt with by this report are in agreement with the books of account;

(d) in our opinion, the aforesaid financial statements comply the Indian Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 and Companies (Indian Accounting Standards) Rules, 2015, as amended;

(e) on the basis of the written representations received from the directors as on 31st March, 2018 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2018 from being appointed as a director in terms of Section 164 (2) of the Act; and

(f) adequacy and effectiveness of the internal controls over financial reporting of the Company is not required to be reported as the Company being a small company covered under exemption provided under the Companies Act, 2013.

(g) with respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigation which might have any impact on its financial position.

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

iv. The reporting on disclosures relating Specified Bank Notes is not applicable for the year ended 31 March 2018.



For J. A. Rajani & Co.
Chartered Accountants
Firm Reg. No. 108331W

P. J. Rajani
P. J. Rajani
Proprietor
Membership No. 116740
Date: 25th May, 2018

**“Annexure A” to the Independent Auditors’ Report of even date on the Financial Statements of
Avery Pharmaceuticals Private Limited**

Referred to in paragraph 1 under the heading ‘Report on Other Legal & Regulatory Requirement’ of our report of even date to the financial statements of the Company for the year ended March 31, 2018 :

- 1) The Company does not hold any fixed assets . Thus, paragraph 3(i) of the Order is not applicable to the Company and hence not commented upon.
- 2) The Company does not hold any physical inventories. Thus, paragraph 3(ii) of the Order is not applicable to the Company and hence not commented upon.
- 3) The Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability partnerships or other parties covered in the Register maintained under section 189 of the Act. Accordingly, the provisions of clause 3 (iii) (a) to (c.) of the Order are not applicable to the Company and hence not commented upon.
- 4) In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 In respect of loans, investments, guarantees, and security.
- 5) The Company has not accepted any deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.
- 6) As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.
- 7) (a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Income-Tax and any other statutory dues with the appropriate authorities. According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at March 31, 2018 for a period of more than six months from the date on when they become payable.

b) According to the information and explanation given to us, there are no dues of income tax, sales tax, service tax, duty of customs, duty of excise, value added tax outstanding on account of any dispute.
- 8) In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks. The Company has not taken any loan either from financial institutions or from the government and has not issued any debentures.
- 9) Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised moneys by way of initial public offer or further public offer including debt instruments and term Loans. Accordingly, the provisions of clause 3 (ix) of the Order are not applicable to the Company and hence not commented upon.
- 10) Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.
- 11) Based upon the audit procedures performed and the information and explanations given by the management, managerial remuneration has not been paid or provided during the year accordingly the provisions of clause 3 (xi) of the Order are not applicable to the Company and hence not commented upon.
- 12) In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 4 (xii) of the Order are not applicable to the Company.



- 13) In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Financial Statements as required by the applicable accounting standards.
- 14) Based upon the audit procedures performed and the information and explanations given by the management, the company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of clause 3 (xiv) of the Order are not applicable to the Company and hence not commented upon.
- 15) Based upon the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order are not applicable to the Company and hence not commented upon.
- 16) In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order are not applicable to the Company and hence not commented upon.



For J. A. Rajani & Co.
Chartered Accountants
Firm Reg. No. 108331W

P. J. Rajani
P. J. Rajani
Proprietor
Membership No. 116740
Place: Mumbai
Date: 25th May, 2018

Avery Pharmaceuticals Private Limited

Balance sheet as at 31st March 2018

(All amounts in Indian Rupees in thousand unless otherwise stated)

Particulars	Note	As at 31st March 2018
Assets		
Non-current assets		
<u>Financial assets</u>		
(i) Other Financial assets	3	2,062
Income tax assets (Net)	4	7
		2,069
Current assets		
<u>Financial assets</u>		
(i) Cash and Cash Equivalents	5	377
		377
TOTAL ASSETS		2,446
Equity and liabilities		
Equity		
(i) Equity Share capital	6	2,500
(ii) Other Equity	7	(63)
Equity attributable to owners of the company		2,437
Current liabilities		
<u>Financial liabilities</u>		
(i) Other Financial liabilities	8	9
		9
TOTAL EQUITY AND LIABILITIES		2,446
Significant accounting policies	2	

The accompanying notes are an integral part of these financial statements (1-18)

As Per our report of even date.



For J. A. Rajani & Co.
Chartered Accountants

P. J. Rajani
Proprietor
Membership No.116740
Place : Mumbai
Date : 25th May 2018

For and on behalf of the Board of Directors
Avery Pharmaceuticals Private Limited

Shripada Patil
Director

Neel Shinde
Director

Avery Pharmaceuticals Private Limited
Statement of profit and loss for the year ended 31st March 2018
 (All amounts in Indian Rupees in thousand unless otherwise stated)

Particulars	Notes	For the year Ended 31st March 2018
Income		
Other income	9	69
Total Income		69
Expenses		
Other Expenses	10	131
Total expenses		131
Profit Before Tax		(63)
Income tax expenses		
Current Tax		-
Total Tax Expenses		-
Profit after tax		(63)
Other Comprehensive Income (OCI)		-
Total comprehensive income for the year, net of tax		(63)
Earnings per equity share		
Basic and Diluted [Nominal value of the shares ₹. 10]	15	(0.25)

The accompanying notes are an integral part of these financial statements (1-18)

As Per our report of even date.



For J. A. Rajani & Co.
Chartered Accountants

P. J. Rajani
P. J. Rajani
 Proprietor
 Membership No.116740
 Place : Mumbai
 Date : 25th May 2018

For and on behalf of the Board of Directors
Avery Pharmaceuticals Private Limited

Shripati Patil
 Director

Sanjay Patil
 Director

Avery Pharmaceuticals Private Limited
Statement of Changes in Equity for the period ended March 31, 2018
 (All amounts in Indian Rupees in thousand unless otherwise stated)

a. Equity shares of INR 10 each issued, subscribed and fully paid

	As at 31st March, 2018	
	Number of shares	Amount
Balance at the beginning	-	-
Changes in equity share capital during the year	250,000	2,500
Balance at the end	250,000	2,500

b. Other Equity

	Reserves and Surplus		
	General Reserve	Retained Earnings	Total
Profit for the year	-	(63)	(63)
Other comprehensive income (net of tax)	-	-	-
Total comprehensive income for the year	-	(63)	(63)
Balance at March 31, 2018	-	(63)	(63)

The accompanying notes are an integral part of these financial statements (1-18)

As Per our report of even date.

For J. A. Rajani & Co.
Chartered Accountants

For and on behalf of the Board of Directors of
Avery Pharmaceuticals Private Limited



P. J. Rajani
Proprietor
Membership No.116740
Place:Mumbai
Date : 25th May, 2018

[Signature]
Director

[Signature]
Director

Avery Pharmaceuticals Private Limited

Notes to Financial Statements for the year ended 31st March, 2018

1 Company Information

The Company is mainly in business of development, manufacturing and trading of pharmaceuticals products

2 Significant Accounting Policies

A Compliance with Indian Accounting Standards (Ind AS):

- a) These Financial Statements (hereinafter referred to as 'Financial Statements') of the Company, have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified under section 133 of the Companies Act, 2013 ('the Act') read with Rule 4 of the Companies (Indian Accounting Standards) Rules, 2015 as amended and other relevant provisions of the Act and accounting principles generally accepted in India. These financial statements were authorized for issue by the Company's Board of Directors on 25th May 2018

Functional and Presentation Currency

These financial statements are presented in Indian rupees, which is the functional currency of the Company. All financial information presented in Indian rupees has been rounded to the nearest thousand, except otherwise indicated.

Basis of measurement

These Financial statements are prepared under the historical cost convention unless otherwise indicated.

Use of Estimates and Judgements

The preparation of the financial statements in conformity with Ind AS requires Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known/ materialise. Estimates and underlying assumptions are reviewed on an ongoing basis.

Information about critical judgments in applying accounting policies, as well as estimates and assumptions that have the most significant effect to the carrying amounts of assets and liabilities within the next financial year, are included in the accounting policies.

- Useful lives of property, plant, equipment and intangibles (Refer note C)
- Measurement and likelihood of occurrence of provisions and contingencies (Refer note E & F)

B Revenue Recognition:

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.

- i) Sale of goods: Revenue from sale of goods is recognized when all the significant risks and rewards of ownership of the goods have been passed to the buyer, usually on delivery of the goods. Sales are net of value added taxes, excise duty and GST.
- ii) Dividend income is accounted for when the right to receive the income is established. Interest income is recognised on time proportion basis taking into account the amount outstanding and the rate applicable.
- iii) Insurance and other claims, where quantum of accruals cannot be ascertained with reasonable certainty, are accounted on acceptance basis.

C Property, Plant and Equipment, Depreciation and Impairment:

i) Property, Plant and Equipment

Property, Plant and Equipment are stated at acquisition cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost of Property, Plant and Equipment includes taxes, duties, freight, borrowing cost, if capitalization criteria are met and other incidental expenses incurred in relation to their acquisition/ bringing the assets for their intended use.

Subsequent expenditures related to an item of Property, Plant and Equipment are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance.



Gains or losses arising from derecognition of plant, property and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

The Company has elected to continue with the carrying value of all its property, plant and equipment as recognized in the financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101.

ii) **Depreciation:**

Depreciation on Property, Plant and Equipment has been provided on written down value basis and manner prescribed in Schedule II to the Companies Act 2013.

D Earnings Per Share

Basic earnings per share are calculated by dividing the net profit or loss after tax for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. For the purpose of calculating diluted earnings per share, the net profit or loss after tax for the year attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

E Provisions

A provision is recognised when an enterprise has a present obligation as a result of past event; it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

F Contingent Liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability but discloses its existence in the financial statements.

G Cash and cash equivalents

Cash and cash equivalent in the Balance Sheet includes cash on hand, cheques on hand, cash at bank, other short term, highly liquid investments with original maturity of three months or less that are readily convertible to known amount of cash and which are subject to an insignificant risk of changes in value.

For the purpose of presentation in the Statement of Cash Flows, cash and cash equivalent includes cash on hand, cheques on hand, cash at bank, other short term, highly liquid investments with original maturity of three months or less that are readily convertible to known amount of cash and which are subject to an insignificant risk of changes in value and overdrawn bank balance.

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future cash receipts or payment and item of income and expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities are segregated

H Financial instruments

Initial recognition and measurement

The Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are recognized at fair value on initial recognition, except for trade receivables which are initially measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, that are not at fair value through profit or loss, are added to the fair value on initial recognition. Regular way purchase and sale of financial assets are accounted for at trade date.

Subsequent measurement

i) **Financial assets amortised at cost**



A financial asset is subsequently measured at amortised cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

ii) Financial assets at fair value through other comprehensive income

A financial asset is subsequently measured at fair value through other comprehensive income if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments principal and interest on the principal amount outstanding.

iii) Financial assets at fair value through profit or loss

A financial asset which is not classified in any of the above categories are subsequently fair valued through profit or loss.

iv) Financial liabilities

Financial liabilities are subsequently carried at fair value through profit and loss. For trade payables and other liabilities maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

Derecognition of financial instruments

Financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire or is transferred and the transfer qualifies for derecognition under Ind AS 109. A financial liability (or a part of a financial liability) is derecognised when the obligation specified in the contract is discharged or cancelled or expires.

Fair value measurement

The Company measures financial instruments such as investments, at fair value at each Balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- a) in the principal market for the asset or liability, or
- b) in the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1: Quoted (unadjusted) market prices in active market for identical assets or liabilities

Level 2: Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3: Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For the purpose of fair value disclosure, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

I Current-non-current classification

All assets and liabilities are classified into current and non-current.



Assets

An asset is classified as current when it satisfies any of the following criteria:

- a) it is expected to be realised in, or is intended for sale or consumption in, the company's normal operating cycle;
- b) it is held primarily for the purpose of being traded;
- c) it is expected to be realised within 12 months after the reporting date; or
- d) it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

Current assets include the current portion of non-current financial assets.
All other assets are classified as non-current.

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

- a) it is expected to be settled in the company's normal operating cycle;
 - b) it is held primarily for the purpose of being traded;
 - c) it is due to be settled within 12 months after the reporting date; or
 - d) instruments do not affect its classification.
- the company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity

Current liabilities include current portion of non-current financial liabilities.
All other liabilities are classified as non-current.

J Taxes on Income

Income tax expense comprises current tax and deferred tax. It is recognised in Consolidated Statement of Profit and Loss except to the extent that it relates items recognised directly in equity or in OCI.

The income tax expense or credit for the period is tax payable on the current year's taxable income based on the applicable income tax rate adjusted by change in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. Management periodically evaluates position taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amount expected to be paid to the tax authorities.

Deferred tax charge or credit and corresponding deferred tax liabilities or assets are measured using the tax rates and laws enacted / substantively enacted at the balance sheet date. Deferred tax assets are recognized and carried forward only to the extent that there is a reasonable certainty, except for carried forward losses and unabsorbed depreciation which is recognized based on virtual certainty, supported by convincing evidence that the assets will be realized in future against future taxable profits

Carrying amount of deferred tax assets are reviewed as at each balance sheet date and are appropriately adjusted to reflect the amount that is reasonably or virtually certain to be realised against future taxable income.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred tax asset and deferred tax liability relate to same taxable entity and the same taxation authority.

Minimum alternate tax (MAT) paid in a year is charged to the Consolidated Statement of Profit and Loss as current tax. The company recognizes MAT credit available as an asset only to the extent that there is convincing evidence that the company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. In the year in which the company recognizes MAT credit as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternative Tax under the Income-tax Act, 1961, the said asset is created by way of credit to the Consolidated Statement of Profit and Loss and shown as "MAT Credit Entitlement." The company reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent the company does not have convincing evidence that it will pay normal tax during the specified period.

K Operating cycle

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.



Avery Pharmaceuticals Private Limited

Notes to Financial Statements for the year ending 31st March, 2018

(All amounts in Indian Rupees in thousand unless otherwise stated)

Particulars	As at 31st March 2018
Note 3	
Other Financial assets	
Fixed deposits with Bank (maturity more than 12 months)	2,062
	2,062
Note 4	
Income tax assets (Net)	
Advance Income Tax (Net of Provision for Taxation of ₹Nil)	7
	7
Note 5	
Cash and Cash Equivalents	
Balance with banks	
On Current Accounts	377
	377



Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended March 31, 2018

(All amounts in Indian Rupees in thousand unless otherwise stated)

Note no. 6 :

a) Equity share capital

Particulars	As at 31st March, 2018	
	No. of shares	Amount
Share Capital		
Authorised share capital		
Equity shares of ₹. 10 each	500,000	5,000
Issued, Subscribed and Paid Up :		
Equity shares of ₹. 10 each fully paid	250,000	2,500
	250,000	2,500

b) Reconciliation of number of shares outstanding at the beginning and at the end of the reporting period

	As at 31st March, 2018	
	No. of shares	Amount
Outstanding at the beginning of the year	-	-
Add: Issue of Equity Share Capital	250,000	2,500
Less:	-	-
Outstanding at the end of the year	250,000	2,500

c) Terms /Rights attached to Equity shares

The company has only one class of equity shares having par value of ₹. 10/- per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

d) Details of shares held by each shareholder holding more than 5% equity shares

Name of Share holder	As at 31st March, 2018	
	No. of Shares	% of Holding
Arrow Greentech Limited	247,500	99.00%
Total	247,500	99.00%



Avery Pharmaceuticals Private Limited

Notes to Financial Statements for the year ending 31st March, 2018

(All amounts in Indian Rupees in thousand unless otherwise stated)

Particulars	As at 31st March 2018
Note 7	
Other Equity	
Profit & Loss account	-
Add: Profit / (Loss) for the year	(63)
	(63)
Note 8	
Other Financial liabilities	
Provision for expenses	9
	9



Avery Pharmaceuticals Private Limited

Notes to Financial Statements for the year ending 31st March, 2018

(All amounts in Indian Rupees in thousand unless otherwise stated)

Particulars	For the year Ended 31st March 2018
Note 9	
Other income	
On Fixed Deposit	69
Total Other Income	69
Note 10	
Other Expenses	
Legal & Professional Charges	119
Payment to Auditors (exclusive of service tax & GST) (refer note no. 16)	9
Miscellaneous Expenses	3
Total Other Expenses	131



Avery Pharmaceuticals Private Limited**Notes to Financial Statements for the year ending 31st March, 2018**

(All amounts in Indian Rupees in thousand unless otherwise stated)

- Balances of Sundry Debtors, Sundry Creditors, Deposits, Loans and Advances are subjected to reconciliation and confirmation, necessary adjustment if required, will be made after reconciliation. The management does not expect any material difference affecting the current year's financial statements.

- The Company does not possess information as to which of its suppliers are covered under micro, small and medium Enterprise Development Act, 2006. However, the company is regular in making payment to its suppliers and has not received any claim in respect of interest for delayed payment.

- Based on the guiding principles given in Ind AS 108 - "Operating segments", the Company is primarily engaged in the business of manufacturing of pharmaceutical products. As the Company's business activity falls within a single primary business segment, the disclosure requirements of Ind AS-108 in this regard are not applicable.

14 Related party disclosures

Related parties with whom transactions have taken place during the year:

Sr.	Name of Related Party	Relationship
1	Arrow Greentech Limited	Holding Company
2	Shilpan Patel	Key Managerial Personnel
3	Neil Patel	

Transaction with Related Parties & Outstanding Balance as on 31st March, 2018:

Sr. No.	Party Name	Transactions for the year ended	Balances receivable/ (payable) as of
		31st March, 2018	31st March, 2018
1	Arrow Greentech Limited (Re - Imbursement of Incorporation Expenses)	94	-
2	Arrow Greentech Limited (Issue of Share)	2,475	-
3	Shilpan Patel (Issue of Share)	25	-

15 Earnings Per Share :

Calculation of basic and diluted EPS is as follows:

Particulars	31st March, 2018
Profit for the year attributable to Owners of the Company	(62.58)
Weighted average number of equity shares	250
Earning per Share Basic / Diluted (Rs.) (On Nominal Value of Rs. 10/- per Share)	(0.25)

16 Payment to Auditors (exclusive of service tax & GST)

Particulars	31st March, 2018
Audit Fees	9
Taxation and Other Matters	-
Total	9



Avery Pharmaceuticals Private Limited

Notes to Financial Statements for the year ending 31st March, 2018

(All amounts in Indian Rupees in thousand unless otherwise stated)

17 Financial Instruments - Accounting Classifications and Fair Value Measurements

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced of liquidation sale.

The following methods and assumptions were used to estimate the fair values:

Fair value of cash and cash equivalent, bank balances other than cash and cash equivalent, trade receivables, trade payables, other current financial liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

Level 1: quoted (unadjusted) prices in active markets for identical assets or liabilities

Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly.

Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

As at March 31, 2018	Carrying value			Fair value			
	Amortised Cost	FVTPL	FVTOCI	Total	Level 1	Level 2	Level 3
Non Current Financial assets							
Other financial asset	2,062	-	-	2,062	-	-	-
	2,062	-	-	2,062	-	-	-
Current Financial assets							
Cash and cash equivalents	377	-	-	377	-	-	-
Other financial assets	-	-	-	-	-	-	-
	377	-	-	377	-	-	-
Total	2,439	-	-	2,439	-	-	-
Current Financial liabilities:							
Trade payables	-	-	-	-	-	-	-
Other financial liabilities	9	-	-	9	-	-	-
Total	9	-	-	9	-	-	-

18 Comparatives for last three years are not available, as company incorporated on 29th May 2017.

As per our Report fo even date.



For J.A Rajani & Co.
Chartered Accountants

P. J. Rajani
Proprietor
Membership No. 116740
Place: Mumbai
Date : 25th May, 2018

For and on behalf of the Board of Directors of
Avery Pharmaceuticals Private Limited

[Signature]
Director

[Signature]
Director